[1] WILCKEN B, WILEY V, HAMMOND J, et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry[J]. N Engl J Med,2003,348(23):2304-2312.
[2] NIU D M, CHIEN Y H, CHIANG C C, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan[J]. J Inherit Metab Dis,2010,33(Suppl 2):S295-S305.
[3] YAMAGUCHI S. Newborn screening in Japan:restructuring for the new era[J]. Ann Acad Med Singapore,2008,37(12 Suppl):13-15.
[4] FEUCHTBAUM L, CARTER J, DOWRAY S, et al. Birth prevalence of disorders detectable through newborn screening by race/ethnicity[J]. Genet Med,2012,14(11):937-945.
[5] LINDNER M, GRAMER G, HAEGE G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases-report of 10 years from South-West Germany[J/OL]. Orphanet J Rare Dis,2011,6:44.
[6] LA MARCA G, MALVAGIA S, CASETTA B, et al. Progress in expanded newborn screening for metabolic conditions by LC-MS/MS in Tuscany:update on methods to reduce false tests[J]. J Inherit Metab Dis,2008,31 Suppl 2:S395-S404.
[7] LIM J S,TAN E S, JOHN C M, et al. Inborn Error of Metabolism (IEM) screening in Singapore by electrospray ionization-tandem mass spectrometry (ESI/MS/MS):an 8 year journey from pilot to current program[J]. Mol Genet Metab,2014,113(1-2):53-61.
[8] SELIM L A, HASSAN S A, SALEM F, et al. Selective screening for inborn errors of metabolism by tandem mass spectrometry in Egyptian children:a 5 year report[J]. Clin Biochem,2014,47(9):823-828.
[9] LEE H C, MAK C M, LAM C W, et al. Analysis of inborn errors of metabolism:disease spectrum for expanded newborn screening in Hong Kong[J]. Chin Med J (Engl),2011,124(7):983-989.
[10] YOON H R, LEE K R, KANG S, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea:a three-year report[J]. Clin Chim Acta,2005,354(1-2):167-180.
[11] ROCHA H, CASTIÑEIRAS D, DELGADO C, et al. Birth prevalence of fatty acid beta-oxidation disorders in Iberia[J]. JIMD Rep,2014,16:89-94.
[12] VILARINHO L, ROCHA H, SOUSA C, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry[J]. J Inherit Metab Dis,2010,33 Suppl 3:S133-S138.
[13] LOUKAS Y L, SOUMELAS G S, DOTSIKAS Y, et al. Expanded newborn screening in Greece:30 months of experience[J]. J Inherit Metab Dis,2010,33 Suppl 3:S341-S348.
[14] RASMUSSEN J, NIELSEN O W, JANZEN N, et al. Carnitine levels in 26,462 individuals from the nationwide screening program for primary carnitine deficiency in the Faroe Islands[J]. J Inherit Metab Dis,2014,37(2):215-222.
[15] SCHULZE A, LINDNER M, KOHLMULLER D, et al. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry:results, outcome, and implications[J]. Pediatrics,2003,111(6 Pt 1):1399-1406.
[16] CHEN Y C, CHIEN Y H, CHEN P W, et al. Carnitine uptake defect (primary carnitine deficiency):risk in genotype-phenotype correlation[J]. Hum Mutat,2013,34(4):655.
[17] BONNEFONT J P, DJOUADI F, PRIP-BUUS C, et al. Carnitine palmitoyltransferases 1 and 2:biochemical, molecular and medical aspects[J]. Mol Aspects Med,2004,25(5-6):495-520.
[18] CHIEN Y H, LEE N C, CHAO M C, et al. Fatty acid oxidation disorders in a chinese population in taiwan[J]. JIMD Rep,2013,11:165-172.
[19] VAN MALDEGEM B T, KLOOSTERMAN S F, JANSSEN W J, et al. High prevalence of short-chain acyl-CoA dehydrogenase deficiency in the Netherlands, but no association with epilepsy of unknown origin in childhood[J]. Neuropediatrics,2011,42(1):13-17.
[20] PENA L, ANGLE B, BURTON B, et al. Follow-up of patients with short-chain acyl-CoA dehydrogenase and isobutyryl-CoA dehydrogenase deficiencies identified through newborn screening:one center's experience[J]. Genet Med,2012,14(3):342-347.
[21] OERTON J, KHALID J M, BESLEY G, et al. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England:prevalence, predictive value and test validity based on 1.5 million screened babies[J]. J Med Screen,2011,18(4):173-181.
[22] HARA K, TAJIMA G, OKADA S, et al. Significance of ACADM mutations identified through newborn screening of MCAD deficiency in Japan[J]. Mol Genet Metab,2016,118(1):9-14.
[23] PUREVSUREN J, HASEGAWA Y, FUKUDA S, et al. Clinical and molecular aspects of Japanese children with medium chain acyl-CoA dehydrogenase deficiency[J]. Mol Genet Metab,2012,107(1-2):237-240.
[24] COUCE M L, SÁNCHEZ-PINTOS P, DIOGO L, et al. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency:regional experience and high incidence of carnitine deficiency[J]. Orphanet J Rare Dis,2013,8:102.
[25] PENA L D, VAN CALCAR S C, HANSEN J, et al. Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database[J]. Mol Genet Metab,2016,118(4):272-281.
[26] EVANS M, ANDRESEN B S, NATION J, et al. VLCAD deficiency:follow-up and outcome of patients diagnosed through newborn screening in Victoria[J]. Mol Genet Metab,2016,118(4):282-287.
[27] 曹金俊,邱文娟,章瑞南,等.极长链酰基辅酶A脱氢酶缺乏症11例的临床和ACADVL基因突变谱分析[J].中华儿科杂志,2015,53(4):262-267. CAO Jinjun, QIU Wenjuan, ZHANG Ruinan, et al. Clinical features and ACADVL gene mutation spectrum analysis of 11 Chinese patients with long chain acyl-CoA dehydrogenase deficiency[J]. Chinese Journal of Pediatrics,2015,53(4):262-267.(in Chinese)
[28] HAN L, HAN F, YE J, et al. Spectrum analysis of common inherited metabolic diseases in Chinese patients screened and diagnosed by tandem mass spectrometry[J]. J Clin Lab Anal,2015,29(2):162-168.
[29] YAMADA K, KOBAYASHI H, BO R, et al. Clinical, biochemical and molecular investigation of adult-onset glutaric acidemia type Ⅱ:characteristics in comparison with pediatric cases[J]. Brain Dev,2016,38(3):293-301.